Press Releases

Date Title
Toggle Summary Kura Oncology Announces Appointment of Kathleen Ford as Chief Operating Officer
Appointment enhances leadership team with focus on strategic planning and operational execution SAN DIEGO , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,
Toggle Summary Kura Oncology to Present at Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer,
Toggle Summary Kura Oncology Reports Second Quarter 2019 Financial Results and Provides Corporate Update
- Registration-directed trial of tipifarnib in HRAS mutant HNSCC ongoing – – Positive Phase 2 trial of tipifarnib in AITL and CXCL12-driven PTCL support potential paths to registration – – Additional Phase 2 data in HRAS mutant HNSCC, other SCCs and AITL anticipated in fourth quarter of 2019 – –
Toggle Summary Kura Oncology to Report Second Quarter 2019 Financial Results
SAN DIEGO , July 25, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2019 financial results after the close of
Toggle Summary Kura Oncology’s Menin-MLL Inhibitor KO-539 Receives Orphan Drug Designation from FDA for Treatment of Acute Myeloid Leukemia
SAN DIEGO , July 24, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Orphan Drug Designation to the
Toggle Summary Kura Oncology Expands Protection for Tipifarnib with New U.S. and European Patents
SAN DIEGO , July 11, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the U.S. Patent and Trademark Office (USPTO) has issued and the European
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , June 21, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the closing of its previously announced underwritten public offering of common stock,
Toggle Summary Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced the pricing of an underwritten public offering of 5,900,000 shares of its common stock at a
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , June 18, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it has commenced an underwritten public offering, subject to market and other conditions,
Toggle Summary Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma
– Primary endpoint achieved with 45% and 42% ORR in AITL and CXCL12+ AITL/PTCL-NOS expansion cohorts – – PTCL patients with tumors characterized by high CXCL12/CXCR4 expression ratio experienced an ORR of 47% and a clinical benefit rate of 82% – – 50% CR rate and 75% ORR observed in AITL patients